America's Blood Centers®
It's About Life.

ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2021 #39 **November 5, 2021**

INSIDE:

OSHA Publishes COVID-19 Vaccination and Testing ETS

The Occupational Safety and Health Administration (OSHA) issued the COVID-19 Vaccination and Testing Emergency Temporary Standard (ETS). "COVID-19 has had a devastating impact on workers, and we continue to see dangerous levels of cases," said U.S. Labor Secretary Marty Walsh in the agency news release announcing the ETS. "We must take action to implement this emergency temporary standard to contain the virus and protect people in the workplace against the grave danger of COVID-19. Many businesses understand the benefits of having their workers vaccinated against COVID-19, and we expect many will be pleased to see this OSHA rule go into effect."

Published in the *Federal Register* on November 5th, the ETS sets forth requirements for employers with 100 employees or more. It notes that OSHA is requesting public comment on the "administrative capacity" of employers with less than 100 employees to implement similar requirements. The ETS is expected to impact two-thirds of all private-sector employees and preempts any state or local requirements.

The is scheduled to take effect immediately stating that Eligible employers must comply with the requirements of the ETS by the following dates:

- thirty days after publication (December 4, 2021): All requirements other than testing for employees who have not completed their entire primary vaccination dose(s);
- sixty days after publication (January 4, 2022): Testing for employees who have not received all doses required for a primary vaccination.

The ETS requires affected employers to implement and enforce a COVID-19 vaccination policy but grants an exception for unvaccinated employees who must be tested regularly and will be subject to a face mask requirement. Specifically, unvaccinated employees must be tested at least weekly (if in the workplace at least once a week) or within seven days before returning to work (if away from the workplace for a week or longer). The ETS does not require employers to pay for the cost of testing. It does require employer documentation of employee vaccination status with certain disclosure requirements as well as requirements for provision of employee information about this ETS.

The ETS applies to employers in all workplaces under OSHA's jurisdiction that have a total of at least 100 employees (firm or corporate-wide). The ETS does not apply to workers that exclusively work from home, work exclusively outdoors, or

(continued on page 2)

OSHA ETS (continued from page 1)

otherwise do not interact in-person with coworkers or customers. When calculating an employer's total employee count, part-time and temporary employees and those working from home are included; independent contractors are not. Once an employer has come within the scope of the ETS, the standard continues to apply for the remainder of the time the standard is in effect, regardless of fluctuations in the size of the employer's workforce.

OSHA states that the ETS does not apply to workplaces covered under the Safer Federal Workforce Task Force COVID-19 Workplace Safety: Guidance for Federal Contractors and Subcontractors or in settings where employees provide healthcare services or healthcare support services when subject to the requirements of the Healthcare ETS (29 CFR 1910.502).

Blood centers are not considered healthcare services or support services under the ETS. OSHA invites public comment on the ETS and how it would be adopted as a final standard. Comments can be submitted electronically in Docket No. OSHA-2021-0007 at www.regulations.gov. America's Blood Centers will continued to provide analysis of the ETS and will provide additional information member blood centers as it becomes available. Please contact ABC's Director of Regulatory Affairs Jill Evans with questions or comments.

(Sources: OSHA News Release, 11/4; OSHA ETS, 11/4)

Upcoming ABC Webinars – Don't Miss Out!

- **ADRP International Showcase** – Nov. 9th. View program and register here.
- **ABC SMT Journal Club Webinar** – Dec. 13th. More details coming soon.

What We're Reading

- Industrially Compatible Transfusable iPSC-Derived RBCs: Progress, Challenges and Prospective Solutions (*International Journal of Molecular Sciences*)
- What Regulators Must Learn from COVID-19 (*Nature Medicine*)

The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail.
ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers
Chief Executive Officer: Kate Fry
Chief Medical Officer: Rita Reik
Editor: Mack Benton
Subscriptions Manager: Leslie Maundy
Annual Subscription Rate: $390

Send subscription queries to
memberservices@americasblood.org
America's Blood Centers
1717 K St. NW, Suite 900, Washington, DC 20006
Phone: (202) 393-5725
Send news tips to newsletter@americasblood.org.

REGULATORY NEWS

The U.S. Food and Drug Administration (FDA) issued a new guidance titled "Manufacture of Blood Components Using a Pathogen Reduction Device in Blood Establishments: Questions and Answers Guidance for Industry." It finalizes "the draft guidance entitled 'Implementation of Pathogen Reduction Technology in the Manufacture of Blood Components in Blood Establishments: Questions and Answers, Draft Guidance for Industry' [from] December 2017." The new guidance addresses specific questions from blood establishments who have implemented pathogen reduction technology (PRT), providing recommendations on reporting the manufacturing changes associated with its implementation. Topics related to the implementation of PRT included within the guidance are:

- donor screening and testing requirements;
- blood product irradiation;
- fractionation of products for further manufacturing;
- platelet agitation requirements;
- cryoprecipitate production;
- temperature requirements;
- red blood cell content requirements;
- validation and quality control;
- ISBT product codes; and
- PAS submission requirements.

America's Blood Centers in consultation with the (ABC) Quality Blood Regulatory Review Committee will continue to review the guidance and provide further communication as needed to member blood centers. Please contact ABC's Director of Regulatory Affairs Jill Evans with questions or comments.

(Source: FDA Guidance, 11/3/21)

The Centers for Medicare and Medicaid Services (CMS) has published the calendar year 2022 "Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Price Transparency of Hospital Standard Charges; Radiation Oncology Model" final rule. It includes a proposed market basket increase of 2.7 percent reduced by a 0.7 percent productivity adjustment for an overall increase of 2.0 percent for hospitals meeting relevant quality reporting requirements. CMS also increased the payment for code P9100 (Pathogen(s) test for platelets) from $32.98 to $54.24 to account for the higher cost of LVDS testing which was not available in the U.S. in 2019 (the year of claims data upon which the current payment rates are based). ABC previously submitted joint comments with AABB and the American Red Cross comments encouraging CMS to change the status indicator for the P9099 unclassified blood product code to ensure appropriate reimbursement for new blood products. We additionally encouraged CMS to provide appropriate reimbursement for large volume delayed sampling (LVDS) of leukocyte-reduced apheresis platelets and leukocyte-reduced whole blood platelets. CMS rejected a request to make changes to the payment rate for the unclassified blood product code and implemented their proposed payment rate of $7.79 per unit for P9099 citing concern that the proposal to provide cost-based reimbursement would be a disincentive for products to seek a HCPCS code should the payment rate be higher. CMS committed to continue exploring other possible ideas in future rulemaking. The final rule has a 30-day comment period. Please contact ABC's Senior Director of Federal Government Affairs Diane Calmus, JD with any questions or comments.

(Source: CMS Final Rule, 11/3/21)

WORD IN WASHINGTON

The U.S. Department of Health and Human Services (HHS) has published a "Health Workforce Strategic Plan." The agency states that the plan is a "forward-looking framework for health workforce improvements, focused on four key goals…This Strategic Plan will facilitate coordinated and intentional efforts to address long-standing barriers to strengthening the health workforce…[It] also aligns with the 'National Strategy for the COVID-19 Response and Pandemic Preparedness' and Presidential Executive Orders related to the COVID-19 pandemic." The plans goals include:

- expand the health workforce to meet evolving community needs;
- improve the distribution of the health workforce to reduce shortages;
- enhance healthcare quality through professional development, collaboration, and evidence-informed practice; [and]
- develop and apply data and evidence to strengthen the health workforce.

(Source: HHS Health Workforce Strategic Plan, 11/4/21)

Doug Parker has been sworn in as the Occupational Safety and Health Administration's (OSHA) Assistant Secretary of Labor. Mr. Parker "[p]reviously served in the Obama Administration as Deputy Assistant Secretary for Policy in the Department of Labor's Mine Safety and Health Administration, and was a member of the Biden-Harris transition team focused on worker health and safety issues. He also held positions as a senior policy advisor and special assistant at the Department of Labor. He most recently served as chief of California's Division of Occupational Safety and Health (Cal/OSHA), a position he held since 2019. Prior to his appointment to Cal/OSHA, Mr. Parker was executive director of Worksafe, an Oakland, California-based legal services provider. Before serving in the Obama Administration, Mr. Parker was a partner at the law firm Mooney, Green, Saindon, Murphy and Welch in Washington, D.C."

(Source: OSHA Announcement, 11/3/21)

The U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and a collection of 15 private organizations comprised of non-profits and pharmaceutical companies announced a partnership to expedite the development of gene therapies. According to an FDA news release, "[t]he newly launched Bespoke Gene Therapy Consortium (BGTC), part of the NIH Accelerating Medicines Partnership (AMP) program and project-managed by the Foundation for the National Institutes of Health (FNIH), aims to optimize and streamline the gene therapy development process to help fill the unmet medical needs of people with rare diseases." Peter Marks, MD, PhD, director of FDA's Center for Biologics Evaluation and Research (CBER) added in the news release, "[b]y leveraging on experience with a platform technology and by standardizing processes, gene therapy product development can be accelerated to allow more timely access to promising new therapies for patients who need them most. DA is committed to developing a regulatory paradigm that can advance gene therapies to meet the needs of patients with rare diseases."

(Source: FDA News Release, 10/27/21)

ABC Calendar of Events

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The calendar of events includes annual and summer meetings, board meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!

America's Blood Centers®
It's About *Life.*

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.

Register for the 60th ABC Annual Meeting

Register today for the 60th ABC Annual Meeting and 25th Annual *Awards of Excellence.* These events will take place March 7th-9th, 2022 at the Ritz-Carlton (Pentagon City) in Arlington, Va. Please secure your hotel reservation today. This year's meeting will be in-person while Advocacy Day will be held virtually the following week given continued visitor restrictions on Capitol Hill. This will allow each blood center to bring together multiple colleagues to connect with their members of Congress and their staff. More information will be provided to ABC members as it becomes available. The ABC Annual Meeting brings together blood center executives and national leaders to discuss advocacy and regulatory updates, the latest in science, medicine, and technical affairs, and hot topics facing the blood community. In addition, ABC is excited to share that the final day of this year's meeting will feature two in-depth training workshops focused on building tangible advocacy skills that can immediately benefit your center. The preliminary program-at-a-glance is available. Please contact ABC Member Services with questions.

2021 ADRP International Showcase on November 9th

ADRP will host the 2021 International Showcase virtually from 1-2:30 p.m. EST on November 9th. Registration is free and open to everyone. The event will feature:

- "Untapped Potential in Elementary Schools – the Future of Blood Donation" by Maryke Harris, Public Relations Practitioner at South Africa National Blood Service;
- "Creating An Outstanding Onboarding Experience to Increase Donor Retention in New Donors" by Isabelle Contu, CX Advisor at Héma-Québec;
- "How and Why Charities Should Provide Feedback to Their Donors" by Lars Eberhart, Head of Donor Management at Blood Center for Vienna, Lower Austria, and Burgenland;
- "Implementation of UK FAIR Recommendations in Scotland" by Dr. Lorna McClintock, Consultant Haematologist and Clinical Lead for Blood Donation at Scottish National Blood Transfusion Service;
- "Donor Recognition – How to Recognize Donors without Incentivizing" by Irene van Schalkwyk, Manager, Marketing Services at New Zealand Blood Service; and
- "A Creative Way to Engage Donors: Challenge Them" by Rufan Li, Chief Marketing Officer at Hoxworth Blood Center.

MEMBER NEWS

LifeSouth Community Blood Centers has been chosen as the official blood provider for the University of Florida (UF) Health Jacksonville and UF Health North according to a report from *Patch*. "We are excited to announce this partnership as an integral part of our expansion in Jacksonville, and we are proud to partner with UF Health to ensure a safe blood supply for their patients here in the Northeast Florida community," said Kimberly E. Kinsell, JD, president and chief executive officer (CEO) of LifeSouth Community Blood Centers. "This extension of our service as the official blood provider of UF Health builds upon many years of partnership with the health system's hospitals across the state. We look forward to saving even more local lives in Jacksonville." Russ Armistead, CEO of UF Health Jacksonville added, "We're proud to expand our partnership with LifeSouth to include service to our Jacksonville health system. Our doctors and patients rely on the generosity of local blood donors to ensure our patients, especially those we serve through our Level I trauma program, receive the best care."

(Source: *Patch*, JAX Chamber: LifeSouth Community Blood Centers selected as the official blood provider of UF Health Jacksonville and UF Health North, 10/27/21)

San Diego Blood Bank recently held a first-time blood drive with U.S. Marshals Service. Steven Stafford, a longtime blood donor and U.S. Marshal for the Southern California District, proposed the drive after hearing how blood shortages had delayed the treatment of five-year-old Karina Willis who is battling leukemia. "I saw this little, bubbly girl that when she is not sick, she is having a good time and I felt really bad that she had to hold off on transfusions that would allow her to feel good." The drive resulted in 60 donors with 37 being first-time donors.

(Source: San Diego Blood Bank Announcement, 10/29/21)

NEW on Coll*ABO*rate

COLLABORATE

SHARE STRATEGIC ADVICE | SOLVE CHALLENGES | DEVELOP NEW APPROACHES

Recent discussion topics on the ABC Coll*ABO*rate Online Member Community include:

- Post-donation Reaction Follow-up (COLLECTIONS & DONOR SERVICES)
- High School Blood Drives (COMMUNICATIONS & DONOR RECRUITMENT)
- RN Performing Telehealth Services (HUMAN RESOURCES)
- Arm Scrubs (QUALITY BYTES)
- Deferral Period for "Cutting" (QUALITY BYTES)
- Hemochromatosis (QUALITY BYTES)

ABC members are encouraged to login and join the conversations today!

We Welcome Your Letters

The *ABC Newsletter* welcomes letters from its readers on any blood-related topic that might be of interest to ABC members. Letters should be kept relatively short and to the point, preferably about a topic that has recently been covered in the *ABC Newsletter*. Letters are subject to editing for brevity and good taste and published after editorial review. Please send letters to the Editor at newsletter@americasblood.org or fax them to (202) 899-2621. Please include your correct title and organization as well as your phone number. The deadline for letters is Wednesday to make it into the next newsletter.

GLOBAL NEWS

An October 29th news release from the World Health Organization (WHO) states that current Director-General Tedros Adhanom Ghebreyesus, PhD will be appointed to another term in May 2022. His second five-year term will officially begin on August 16th. The role of WHO Director-General serves as the organization's chief technical and administrative officer. Dr. Ghebreyesus was the only candidate proposed by 28 of the WHO's member nations that submitted nominations for the role.

(Source: WHO News Release, 10/29/21)

COMPANY NEWS

Biotest AG recently announced the findings from an analysis of data from the Escape from severe COVID-19 (ESsCOVID) trial of the company's immunglobin therapy (trimodulin) for hospitalized patients with COVID-19. According to a news release, the multinational phase II clinical trial included 166 hospitalized patitents "with pneumonia or acute respiratory distress syndrome (ARDS)" who tested positive for COVID-19. The primary endpoint "as to prevent patients from worsening (e.g. need for invasive mechanical ventilation) and to prevent death of the patients…Initial data showed that the primary endpoint of the trial was not met in the overall trial population, which included also patients with an already advanced systemic inflammation. However, the detailed *post-hoc* analyses of the complete data set revealed a notable benefit in a relevant subgroup of hospitalised patients with early systemic inflammation. In this subgroup of 96 COVID-19 patients trimodulin was able to markedly reduce both worsening and mortality of patients compared to placebo treated patients." The trial found "[n]o relevant safety concerns have been identified confirming the good safety profile of trimodulin…Biotest considers the reduction of deterioration and mortality rate as a relevant medical benefit indicative to continue the development of trimodulin in this target population."

(Source: Biotest AG News Release, 10/11/21)

FCI Promos will soon become FCI Brands. The company will be unveiling a new look to accompany the new name in the coming weeks. According to the email announcement, the change in part signifies the company's expansion of services over the years to provide organizations with marketing, promotional and printing solutions.

(Source: FCI Promos Email Announcement, 10/26/21)

Eli Lilly "has retracted" an approval request to the European Medicines Agency (EMA) for the company's monoclonal antibodies cocktails (etesevimab and bamlanivimab). According to a report from *Reuters*, the retraction by Eli Lilly is due to "a lack of demand from EU member states as the bloc focuses on other suppliers." The monoclonal antibody cocktail has received emergency use authorization from the U.S. Food and Drug Administration "for patients at an early stage of the disease to prevent deterioration and for some people who have been exposed to the virus." *Reuters* also reported that the U.S. government recently agreed to purchase 614,000 additional doses of the antibody cocktail.

(Source: *Reuters*, Lilly pulls COVID-19 treatment from EU review while U.S. stocks up, 11/2/21)

CALENDAR

Note to subscribers: *Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org or by fax to (202) 899-2621. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)*

2021

Dec. 6-8. **American Association of Tissue Banks (AATB) Annual Meeting (Virtual).** Registration is open.

Dec. 1. **U.S. Department of Health and Human Services (HHS) Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) (Virtual).** More information available soon.

2022

Mar. 7-9. **ABC Annual Meeting, Washington, D.C.** Registration is open. More information available here.

May 10-12. **2022 ADRP Conference, Phoenix, Ariz.** Additional details coming soon.

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: $139 per placement for *ABC Newsletter* subscribers and $279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Divisional Supervisor of Clinical Service (Charleston, SC Region). The Divisional Supervisor of Donor Services provides direct supervision for mobile staging and operational support staff. This position is responsible for collections staff scheduling and coordinating staff changes post release of schedule. The Divisional Supervisor participates in staff call duties, performs bus driver duties (if applicable), and donor collection duties when required. Other responsibilities include submitting weekly time records for staff and assisting with daily QC review. Essential Operational Functions: Ensures supply of non-warehouse forms/tags used on mobiles and fixed sites are adequate. Assists with departmental equipment validations. Ensures mobile and center staging pods are adequately stocked and made available to outgoing blood drives and/or fixed site centers in a timely fashion. Ensures equipment returning from inside set-up drives are properly stored, and if required, charged. Ensures all box trucks are clean, organized, have adequate supplies and equipment upon return and prior to every departure. Other duties as assigned or acquired. Minimum Qualifications: High School Diploma or GED. Valid Driver's License with no major infractions and dependable transportation. Experience in mobile and apheresis collections required. Ability to organize and prioritize workload and meet deadlines. Ability to establish and maintain effective working relationships with staff, management, and peers. Please click here to apply.

QRA Supervisor (Req#: R219667). Reporting to the Regulatory & Accreditation Compliance Director, the QRA Supervisor is responsible for carrying out day-to-day activities at the Stanford Blood Center Quality & Regulatory Affairs department by appropriate management of the QRA Specialist, ensure timely review of records and completion of QRA activities. Assume the responsibility SBC safety initiatives, disaster preparedness, and support continuity of operation across the organization. Responsibilities: Quality Assurance/Training/ GMP/GTP/GLP: Lead the department's quality activities, initiatives, and process improvement activities. Perform training on QRA core functions and activities, Good Manufacturing Practice/Good Tissue Practice/Good Laboratory Practice, and safety. Compliance: Ensure compliance to current regulations and accreditation requirements by federal, state, county, and accreditation agencies. Team Leadership: Manage the performance of direct reports. Set team objectives, priorities, and resources to align staff with Blood Center objectives. Responsible for interviewing, hiring, training, coaching, performance management, and performance reviews of direct reports. Safety: Lead the safety, emergency, and disaster management. Quality Management System: Provide oversight on the appropriate use of the quality management tools in handling the various documents, records, and activities of the blood center. Qualifications: Bachelor's Degree Required. One plus year to two years in a regulated or GMP (Good Manufacturing Practice) required. Click here to apply.

(continued on page 9)

POSITIONS (continued from page 8)

Director, Donor Recruitment. LifeStream, a local non-profit organization providing blood services for more than 80 hospitals in Southern California, is searching for a Director, Donor Recruitment to lead the Donor Recruitment Team. Reporting to the Vice President, Operations, and managing a staff of 16 employees, the Director of Donor Recruitment is responsible for developing and deploying cohesive recruitment strategies to increase annual collections through the acquisition of new blood donors, new donor groups, and increased frequency of current donors. Also responsible for aligning staffing resources at all Donor Centers and Mobile Blood Drives to ensure daily, monthly, and annual collection goals are efficiently achieved. This individual will monitor operational performance data to ensure effective and efficient use of staffing resources to achieve desired collection targets. This position works closely with multiple departments to ensure successful drives. The ideal candidate will possess a bachelor's degree (BA) in Business, Marketing, Public Relations, or related field. Or three to five years sales management experience, leading a successful sales/recruitment team. Strong management/sales experience required. Must have proven and significant growth record in territories and/or sales. Demonstrated experience in sales/territory management skills, strong leadership and team building skills, excellent verbal and written communication and public speaking skills required. Bilingual a plus. Apply online: www.LStream.org. E-mail: recuitment@LStream.org. EOE.

Clinical Laboratory Scientist - MT Certified. LifeSouth Community Blood Centers is currently seeking Level III Clinical Laboratory Scientists in Stone Mountain, GA. This position is responsible for performing and interpreting clinical laboratory tests that require the exercise of independent judgment. Must be MT certified; confirmatory testing experience preferred. Applicants should apply here: https://lifesouth.csod.com/ux/ats/careersite/5/home/requisition/2342?c=lifesouth.

MT / MLS (Carter BloodCare – Fort Worth, Texas). Principal Accountability: The Medical Technologist 1 (MT 1) will report to the Manager or designee of Reference & Transfusion (R&T) Services at John Peter Smith (JPS) located in Fort Worth, TX. The incumbent will participate in all activities in the R&T Services to include but not limited to: Support Carter BloodCare's (CBC) vision, mission, and core values. Maintain compliance with the CBC's attendance policies and department schedules as outlined in the CBC Employee Handbook. Perform testing and services associated with assigned departmental duties. These duties are in the scope of complexity according to accrediting agencies. Participation in competency, proficiency, and educational opportunities. Education: Bachelor's Degree required. Medical Technologist: MT(ASCP), BB(ASCP), MT(AMT) or equivalent certification required. Experience: Recent graduate from an accredited Clinical Laboratory Sciences (CLS) program within the last five years and currently board eligible. NOTE: Must successfully obtain, maintain board certification (i.e., MLS(ASCP) or equivalent) and provided board certification documentation to the CBC Human Resources department within 12 months of hire date. Equal Opportunity Employer: Disability/Veteran. Apply at www.carterbloodcare.org, click Careers & search Req # 26791 or 26430.

MT / MLS (Carter BloodCare – Bedford, Texas). Principal Accountability: The Medical Technologist 1 (MT 1) will report to the Manager or designee of Reference & Transfusion (R&T) Services in Bedford, Texas. The incumbent will participate in all activities in the R&T Services to include but not limited to: (1) Support Carter BloodCare's (CBC) vision, mission, and core values. (2) Maintain compliance with the CBC's attendance policies and department schedules as outlined in the CBC Employee Handbook. (3) Perform testing and services associated with assigned departmental duties. These duties are in the scope of complexity according to accrediting agencies. (4) Participation in competency, proficiency, and educational opportunities. Education: Bachelor's Degree required. Medical Technologist: MT (ASCP), BB(ASCP), MT(AMT) or equivalent certification required. Experience: Recent graduate from an accredited Clinical Laboratory Sciences (CLS) program within the last five years and currently board eligible. NOTE: Must successfully obtain, maintain board certification (i.e., MLS(ASCP) or equivalent) and provide board certification documentation to the CBC Human Resources department within 12 months of hire date. Equal Opportunity Employer: Disability/Veteran. Apply at www.carterbloodcare.org, click Careers & search Req # 29048 or 28777.

Clinical Apheresis RN (Carter BloodCare). Principal Accountability: The Clinical Apheresis Registered Nurse (CARN) collects leukocytes and performs therapeutic apheresis procedures for Carter BloodCare (CBC) clients in and around the Dallas/ Fort Worth area. The CARN follows CBC Standard Operating Procedures (SOP) assesses and monitors patient/donor while receiving an apheresis treatment; contacts patient physicians or a CBC Medical Director as situation warrants for medical consults for clarification of orders, transfusion reactions and/or emergency situations; and ensures that excellent customer service is provided to CBC customers at all times. Regular full-time attendance is required during office hours. Education: RN with active unencumbered licensure in the State of Texas. CPR Certification. Experience: Minimum one (1) year nursing experience in a hospital setting, oncology unit, or clinic. Intensive care unit, dialysis, ER, oncology, and/or pediatric experience

(continued on page 10)

POSITIONS (continued from page 9)

preferred. Apheresis experience preferred. Equal Opportunity Employer: Disability/Veteran. Apply at www.carterbloodcare.org, click Careers & search Req # 26045 or 25152.

Clinical Apheresis Manager (Carter BloodCare). Principal Accountability: The Manager of Clinical Apheresis Services is responsible for meeting Carter BloodCare and departmental objectives. The Manager is responsible for ensuring excellent customer service and managing issues. The Manager provides oversight for a team of nurses and apheresis collection technicians who perform therapeutic procedures on hospitalized patients for treatment of disease, or collection of cells from donor or patient peripheral blood for various cell therapy treatments or research projects. The Manager is responsible for managing daily operations, business activities, and quality patient care. The position is responsible for staffing field assignments, and performing procedures in the field to assist in training or as staffing indicates. Also, the Manager is responsible for maintaining statistics and quality indicators of procedures and records of preventative or responsive maintenance along with quality control of supplies and equipment. Regular full-time attendance is required during office hours. Education: Bachelor of Science in Nursing. RN active licensure in the State of Texas, preferably with Hemapheresis Practitioner (HP) or Qualification in Apheresis (QIA) credentialing. Experience: At least five years' apheresis experience of which three years should be in therapeutic/PBSC apheresis. Two years' management experience required. Equal Opportunity Employer: Disability/Veteran. Apply at www.carterbloodcare.org, click Careers & search Req # 27905.

Assistant Manager of Contact Center (Carter BloodCare). Principal Accountability: The Assistant Manager will be responsible to the Manager of Donor Communications, for managing motivating, and mentoring Donor Communications personnel toward achieving assigned production goals for Carter BloodCare. This individual will be responsible for the creation of call lists and preparation of performance reports by collecting, analyzing, and summarizing data and trends and meet with manager to present findings and solutions. All duties and responsibilities must be performed in compliance with Standard Operating Procedures and organizational policies. Regular full-time attendance is required during office hours. Position will require early morning, late evening, weekend, and Holiday hours. Education: High School Diploma or GED equivalent required. Four-year college degree preferred. Experience: Two or more years of direct supervisory experience preferred in a highly customer service-oriented environment. One to two years of database experience required. Two or more years of call center experience a plus. Equal Opportunity Employer: Disability/Veteran. Apply on our website, click "Careers" & search Req # 29054.